Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cool. I'm pretty much a biotech investor. I like watching clinical results from start-ups...had some success...five of my larger investments have been acquired. A couple have nosedived into oblivion.
Like the comparison to Biogen...That's what I meant when I said that 12 months from now this will look like a "little" rally.
I bought most of my shares at 40-50cents us
I still see the stock as undervalued, highly undervalued
started buying at the 2015 biotech showcase during Don's presentation. it was already up a decent amount about an hour after he finished.
I thought about it for a few minutes and then bought just a few more.
hahahahaha broke my rule! but only 1k.
I thought about it for a few minutes and then bought just a few more.
hahahahaha broke my rule! but only 1k.
I play the same way. No more than 10% on RVX though. Usually just a few k
It will definitely look like a little rally when we look back 12 months from now
possible but unlikely given the past
Good decision (IMO). did the same
This is a nice little rally anticipating results.
But the point is that you can make substantial returns with this kind of crap. The rules are simple. Watch your predictor (mine is RSI). Don't fall in love. Take profit.
Fairly successful P 'n D. Congrats to all who took advantage of it. I sold too early at .24 but I will take the 2x anytime.
Still expect the 10Q to be weak.
Good luck to all the longs here. Looks like the run has some legs
Attached please find RedHill Biopharma’s press release announcing that it has submitted a New Drug Application (NDA) to the U.S. FDA for Talicia (RHB-105) for the treatment of H. pylori infection.
The NDA follows a recent positive pre-NDA meeting with the FDA.
The NDA for Talicia is eligible for six-month priority review.
Talicia is eligible for a total of eight years of U.S. market exclusivity, in addition to patent protection until at least 2034.
RedHill continues to strengthen its U.S. commercial operations with senior industry executives ahead of the planned commercial launch of Talicia, as early as Q4/2019.
H. pylori bacterial infection is the strongest risk factor for developing gastric cancer and affects over 50% of the population worldwide and approximately 35% of the U.S. population.
Current standard-of-care therapies fail in approximately 30-40% of patients due to increasing resistance to antibiotics commonly used in standard combination therapies; notably, no resistance to rifabutin, a key component of Talicia, was detected throughout the Phase 3 ERADICATE Hp2 study.
Talicia has the potential to become the new first-line standard-of-care therapy for H. pylori infection, targeting an estimated 2.5 million U.S. patients treated annually.
Gilead Raday, RedHill’s chief operating officer, stated: "The NDA submission for Talicia is a transformative milestone for RedHill and a critical step in our efforts to bring this much needed potential new therapy for H. pylori infection to the market. Assuming FDA approval, commercial launch is planned for the fourth quarter of 2019 with our established U.S. sales force, led by a highly experienced commercial management team.”
Ira Kalfus, M.D., RedHill’s medical director, said: “Talicia demonstrated robust results in its clinical studies for H. pylori infection, a common and increasingly resistant and difficult to treat pathogen. Importantly, in our clinical study, no H. pylori resistance to rifabutin, one of the key ingredients in Talicia, was identified pre and post treatment. We believe Talicia has the potential to become the new first-line, standard-of-care therapy for H. pylori infection and would like to thank the patients, investigators and clinical support staff who were involved in the clinical studies of this important potential new therapy.”
What is your expectation re the 10q?
This is the kind of thing that IPIX longs for.
How about that other Canadian company?
yes...not me...at least not yet.
(although I held around 70k from the last run)
hallleluyah
...and out!
This time with a doubler. not optimistic about the 10Q
So this 10Q should be the one, right?
I hope you are right about the run-up, but I don't share your optimism about it happening today
"In determining the valuation of the Company, we looked at various scenario’s with subsequent valuations. In each of these scenarios we assumed a reduction in MACE of at least 25% with secondary endpoints of potential improved renal risk marker eGFR and cognitive marker MoCA score improvement of at least 10-20% and 1.0-2.0 points respectively relative to placebo group. We feel that a potential reduction of MACE of greater than 35% and even 40% is possible and therefore have provided sensitivity and enhanced value modelling for these efficacy endpoints if reached. We have increased our valuation with the publication of topline data to be expected within 2-3 months. We believe that Resverlogix remains gravely undervalued at the current share price of CAD 4.05. We feel that the company’s potential for MACE reduction of greater than 30% is possible and as a result suggest that the current total value should be of CAD 3.5-4.6 billion, or CAD 17.50-23.07 per share. This represents a substantial upside from the current share price."
https://nebula.wsimg.com/fd518ad15f5af37452a82a086c484d66?AccessKeyId=F1B3D293B900048B2E3E&disposition=0&alloworigin=1
The reduced cash requirement is not surprising given that the loan is largely paid
Kicking the can down the road. And not very far. Inflection point coming for sure.
History does tend to repeat. Tediously, perhaps, but excitement and disruption as alternatives are not always positive.
Ha!
There are probably many who, like you, look to lock in profit before results are released. This will likely contain the price run-up prior to results.
what makes me nervous is the possibility of missing the primary and hitting the secondaries. I have no evidence to back up my angst. It is just there.
sometimes you get lucky
here is the latest corporate presentation.
https://ir.redhillbio.com/static-files/7b018c0b-a4fc-4e51-a03b-0c904dfa206e
And now that it is heading back up that may have been blind luck!
decided to buy them back today instead of waiting for 2.60. back to full strength....and a few k extra
tough stock to flip but I managed a few.
NDA coming soon for Talicia. Good time to be in RDHL
F L U F F !
Second day of the run up. Gotta love it
you see the "other" R today? (RVXCF)
I was told p1 start early 2020. That was 3 months ago
getting tempting....
hahahahaha Beautiful day here and I was outside from about 5 minutes after market open until a bit ago. It is now an even more beautiful day....
News or fluff?